DRKS00032186RecruitingNot Applicable
Development of a method for secondary and tertiary prevention of head and neck tumors - OncSaliva
niversitätsklinikum Jena, Klinik für Hals-, Nasen- und Ohrenheilkunde0 sites100 target enrollmentStarted: July 3, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to one (—)
- Sex
- All
Inclusion Criteria
- •- with head and neck tumours
- •- Men and women who come to the scene for the clarification of symptoms with suspicion for malignancy in the head and neck area in the otolaryngology clinic,
- •- Primary tumors and recurrent tumors
- •- HPV-independent (HPV+ and HPV-)
- •- Age = 18 years
- •- Patients without head and neck cancer who have undergone surgery
- •tissue is obtained from the oropharynx, e.g. with recurrent
- •Tonsillitis who present for tonsillectomy
Exclusion Criteria
- •- Salivary gland malignancies
- •-Lack of consent
Investigators
Similar Trials
Completed
Not Applicable
Development, implementation and evaluation of two tailored based physical activity intervention for the over-fifties.Externe factoren van ziekte en sterftenvtNL-OMON29808niversiteit Maastricht2,000
Recruiting
Not Applicable
The development of a new method for evaluation of glaucoma (The relationship between ocular circulation and neural activity in glaucoma patients)glaucomaJPRN-UMIN000023960Asahikawa Medical University50
Active, not recruiting
Not Applicable
Entwicklung einer Untersuchungsmethode zur Bestimmung des NO-Transferfaktors der Lunge Evaluierung der Methode und Normwerterhebung an gesunden Probanden(Development of a new method for steady-state measurement of NO lung diffusing capacity in healthy subjects)ung function testing (NO- and CO Transferfactor) in healthy subjectsEUCTR2005-005678-61-DEniversity Hospital Tuebingen107
Active, not recruiting
Phase 1
An extension to a phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome-positive leukemia including acute lymphoblastic leukaemia, acute myeloid leukaemia, and accelerated phase chronic myeloid leukemia - N/APhiladelphia chromosome-opositive chronic myeloid leukamia in myeloid blast crisisEUCTR2004-001396-19-GBovartis Pharmaceuticals UK Ltd293
Active, not recruiting
Not Applicable
An extension to a phase II study to determine the safety and the anti- leukemic effects of STI571 in adults patients with Philadelphia chromosome positive leukemia including acute lymphoblastic leukemia, acute myeloid leukemia and accelerate phase myeloid leukemia.Philadelphia chromosome positive leukemia including acute lymphoblastic leukemia, acute myeloid leukemia and accelerate phase myeloid leukemia.MedDRA version: 14.1Level: HLTClassification code 10024296Term: Leukaemias chronic myeloidSystem Organ Class: 100000004851EUCTR2005-001381-14-ITOVARTIS FARMA294